AZTA Prakiraan rega marang bathi Azenta Inc

Azenta, Inc. (AZTA) is leveraging the development of cell therapy and asset optimization to strengthen its balance sheet. The issuer's forward P/E visualizes market value relative to expected earnings, where 57.40 represents the latest metric reading. Despite pressure from corporate behemoths, Azenta, Inc. (AZTA) maintains its position in biobanking through the implementation of autonomous cryogenic robots that eliminate human error when handling samples.

AZTA - Kapitalisasi marang proyeksi bathi azenta.com ing rentang 04.07.2022 - 12.11.2026

Rincian metrik keuangan lan pasar Brooks Automation (AZTA)

- nilai saham lan prakiraan konsensus rega:

Bagan rega Azenta|AZTA - Target median analis

- data kapitalisasi pasar:

Biji pasar Azenta Inc|AZTA - Total Nilai Bisnis

- statistik nilai buku emiten:

Nilai Buku saben Saham Azenta|AZTA - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku azenta.com|AZTA - Gunggung Aset Perusahaan

- informasi babagan utang lan solvabilitas:

- statistik bathi lan rasio pasar:

AZTA - Asil keuangan resik|Proyeksi bathi mangsa ngarep Azenta, Inc.|AZTA - Koefisien rega marang bathi|Pangali Forward P/E Azenta Life Sciences|AZTA - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Azenta Inc|AZTA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Azenta|AZTA - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan azenta.com|AZTA - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Azenta, Inc.

Analisis fundamental perusahaan:Azenta

Azenta, Inc. (AZTA) provides the biopharmaceutical sector and laboratories with critical cryostorage systems and genomic technologies. The forward P/E ratio compares the current share price with projected annual earnings, determining market expectations for business efficiency. High values indicate overbought conditions, while low values suggest undervalued assets. It is essential for investors to monitor valuation boundaries to minimize risks. By analyzing the fluctuations of the company's forward P/E on GURU.Markets, one can identify optimal entry points.

Pesaing Azenta, Inc. (AZTA)

Rega marang bathi mangsa ngarep Abbott (ABT)|Kapitalisasi marang proyeksi bathi Thermo Fisher Scientific Inc.|GE Healthcare Corp - Prakiraan rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep MTD (Mettler Toledo Inc)|Waters Corporation - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi bio-techne.com TECH|BRKR: Pangali Forward P/E|Prakiraan rega marang bathi Varex Imaging Corp|Prakiraan rega marang bathi SMLR|BFLY: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Mesa Laboratories, Inc. (MLAB)|Prakiraan rega marang bathi quantum-si.com QSI|Pangali Forward P/E NNOX (Nano-X)|Quanterix Corp. (QTRX) - Rasio prakiraan rega marang bathi|908 Devices Corp - Pangali Forward P/E|CV (CapsoVision Inc) - Rasio rega marang bathi mangsa ngarep|MXCT: Pangali Forward P/E|RPID - Kapitalisasi marang proyeksi bathi|SEER (Seer) - Pangali Forward P/E|Prakiraan rega marang bathi Hyperfine Inc (HYPR)|Pangali Forward P/E FONR|Pangali Forward P/E daxor.com (DXR)|Rega marang bathi mangsa ngarep Spectral AI MDAI|organovo.com - Rega marang bathi mangsa ngarep|ACON: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi AKYA (Akoya Biosciences)|THMO: Pangali Forward P/E|Rasio prakiraan rega marang bathi Talis Biomedical Corporation (TLIS)|Rega marang bathi mangsa ngarep T2 Biosystems, Inc.